Hedge Fund - RA Capital Management
Ascendis Pharma A/S (ASND)
Holding History Records
| No. | Filing Period | Value | % of Portfolio | Number of Shares | Avg. Quarterly Share Price |
|---|---|---|---|---|---|
| 1 | 2023 - Q4 (2023-12-31) | $1,273,027,030 | 19.88% | 10,107,400 | $99.70 |
| 2 | 2023 - Q3 (2023-09-30) | $1,003,779,130 | 19.76% | 10,719,555 | $93.55 |
| 3 | 2023 - Q2 (2023-06-30) | $1,001,863,112 | 18.91% | 11,225,357 | $87.09 |
| 4 | 2023 - Q1 (2023-03-31) | $745,948,732 | 16.88% | 6,957,179 | $114.40 |
| 5 | 2022 - Q4 (2022-12-31) | $849,680,271 | 17.23% | 6,957,179 | $116.10 |
| 6 | 2022 - Q3 (2022-09-30) | $781,462,000 | 16.67% | 7,567,900 | $94.81 |
| 7 | 2022 - Q2 (2022-06-30) | $703,512,000 | 18.75% | 7,567,900 | $94.25 |
| 8 | 2022 - Q1 (2022-03-31) | $888,169,000 | 19.37% | 7,567,900 | $115.81 |
| 9 | 2021 - Q4 (2021-12-31) | $1,018,110,000 | 17.94% | 7,567,900 | $148.75 |
| 10 | 2021 - Q3 (2021-09-30) | $1,177,557,000 | 16.31% | 7,387,900 | $136.86 |
| 11 | 2021 - Q2 (2021-06-30) | $895,374,000 | 14.37% | 6,806,341 | $133.25 |
| 12 | 2021 - Q1 (2021-03-31) | $826,408,000 | 12.46% | 6,412,228 | $151.98 |
| 13 | 2020 - Q4 (2020-12-31) | $978,221,000 | 13.67% | 5,865,338 | $165.37 |
| 14 | 2020 - Q3 (2020-09-30) | $911,991,000 | 16.68% | 5,909,742 | $143.74 |
| 15 | 2020 - Q2 (2020-06-30) | $726,922,000 | 14.16% | 4,914,955 | $137.30 |
| 16 | 2020 - Q1 (2020-03-31) | $553,473,000 | 17.48% | 4,914,955 | $129.93 |
| 17 | 2019 - Q4 (2019-12-31) | $582,265,000 | 17.65% | 4,185,342 | $111.10 |
| 18 | 2019 - Q3 (2019-09-30) | $398,037,000 | 23.71% | 4,132,442 | $111.55 |
| 19 | 2019 - Q2 (2019-06-30) | $475,851,000 | 25.54% | 4,132,442 | $119.66 |
| 20 | 2019 - Q1 (2019-03-31) | $486,388,000 | 20.97% | 4,132,442 | $87.57 |
| 21 | 2018 - Q4 (2018-12-31) | $265,670,000 | 15.46% | 4,240,536 | $62.83 |
| 22 | 2018 - Q3 (2018-09-30) | $300,484,000 | 16.06% | 4,240,536 | $68.83 |
| 23 | 2018 - Q2 (2018-06-30) | $282,080,000 | 18.31% | 4,240,536 | $65.76 |
| 24 | 2018 - Q1 (2018-03-31) | $277,331,000 | 21.24% | 4,240,536 | $56.20 |
| 25 | 2017 - Q4 (2017-12-31) | $223,562,000 | 18.7% | 5,580,690 | $36.36 |
| 26 | 2017 - Q3 (2017-09-30) | $202,300,000 | 18.27% | 5,580,690 | $28.70 |
| 27 | 2017 - Q2 (2017-06-30) | $154,920,000 | 17.77% | 5,580,690 | $26.42 |
| 28 | 2017 - Q1 (2017-03-31) | $151,480,000 | 18.58% | 5,409,990 | $25.27 |
| 29 | 2016 - Q4 (2016-12-31) | $109,498,000 | 15.99% | 5,409,990 | $19.97 |
| 30 | 2016 - Q3 (2016-09-30) | $73,998,000 | 7.63% | 3,681,491 | $16.51 |
| 31 | 2016 - Q2 (2016-06-30) | $45,289,000 | 6.27% | 3,412,857 | $15.41 |
| 32 | 2016 - Q1 (2016-03-31) | $40,093,000 | 5.12% | 2,161,366 | $17.76 |
| 33 | 2015 - Q4 (2015-12-31) | $30,621,000 | 3.03% | 1,671,447 | $17.53 |
| 34 | 2015 - Q3 (2015-09-30) | $25,864,000 | 3.71% | 1,461,268 | $19.47 |
| 35 | 2015 - Q2 (2015-06-30) | $33,825,000 | 3.4% | 1,913,153 | $17.50 |
| 36 | 2015 - Q1 (2015-03-31) | $17,760,000 | 1.79% | 1,023,652 | $18.18 |
The displayed share prices are average quarterly stock market prices.